Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Sunday, September 13, 12:42 PM
| This Slide: #149 of 668 |
Slide #149. Celsion Corporation — Preferred Stock Offering
| Company: | Celsion Corporation (CLSN) |
| Date announced: | 1/10/2022 |
| Shares Offered: | 50,000 |
| Date of Pricing: | 1/10/2022 |
| Price Per Share: | $285.00 |
| Preferred Stock Offering Details: | Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 50,000 shares of Series A convertible redeemable preferred stock and 50,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $285, representing an original issue discount of 5% of the $300 stated value of each share. Each share of Series A preferred stock is convertible into shares of Celsion's common stock at an initial conversion price of $0.91 per share. Each share of Series B preferred stock is convertible into shares of Celsion's common stock at an initial conversion price of $1.00 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of stockholder approval for a reverse stock split of the Company's common stock. Celsion will be permitted to compel conversion of the Series A and Series B preferred stock after the fulfillment of certain conditions and subject to certain limitations. Total net proceeds from the offerings, before deducting the placement agent's fees and other estimated offering expenses, is approximately $28.5 million. |
Celsion is a clinical stage biotechnology company. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for the treatment of ovarian cancer. ThermoDox®, Co.'s proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications, which is being managed though Co.'s wholly owned subsidiary, Celsion GmbH. Additionally, Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Open the CLSN Page at Preferred Stock Channel »
|
|||||||||
|
|
Open the CLSN Page at Preferred Stock Channel (in a new window) »
|
Browse preferred stock yield screens, safer-income pages, offerings research, valuation and liquidation-preference screens, and related market idea pages from across the channel network. These links are grouped by topic to make the list easier to scan. Preferred Yield and Income ScreensCore PreferredStockChannel pages focused on high-yield preferreds, socially responsible income ideas, and safer-income preferred research. Offerings, Structure, and Screening ToolsPages for recent preferred offerings, preferreds by index membership or industry, and insider-related screening ideas. Premium, Discount, and Relative Value ScreensPages centered on preferred stock pricing relative to liquidation preference and comparative value signals. Dividend and Cross-Network Income ResearchRelated dividend and income pages from across the network that support preferred-stock investors comparing income vehicles. Analyst and Broader Market ResearchBroader analyst and market pages that remain part of the live homepage inventory. |
|
|
